Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research and Development »
« Back
Partnerships
Careers
Citizenship »
« Back
- Scientist Development Program
- Aclaris Support
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research and Development »
« Back
Partnerships
Careers
Citizenship »
« Back
- Scientist Development Program
- Aclaris Support
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Presentations

Investor Presentations

ATI-052 POC Trial results in AD and Asthma

ATI-052 POC Trial results in AD and Asthma

Corporate Update Presentation

August 2026 Corporate Presentation

ATI-052: Full SAD MAD Results thumb

ATI-052 full SAD/MAD results + ATI-2138 update

ATI-2138 Phase 2a Top-Line Results

ATI-2138 Phase 2a Top-Line Results

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2026 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.